Elanco completes $120 million Elwood, Kansas biologics manufacturing expansion

• Elanco completed a 25,000-square-foot expansion at its Elwood, Kansas manufacturing site to scale monoclonal antibody production capacity.
• Project lifts site output by more than four times via new upstream and downstream processing equipment.
• Investment totals USD 120 million, adding a pilot plant, a quality control lab, support space.
• Additional USD 30 million of spending is planned through 2028 for warehousing, taking total investment to USD 150 million.
• Expanded capacity supports ramp-up of Befrena demand, with supply expected to reach unconstrained levels in early 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elanco Animal Health Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608260830PR_NEWS_USPR_____DE33794) on August 26, 2026, and is solely responsible for the information contained therein.